Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMERALD-3: Durvalumab + Tremelimumab ± Lenvatinib with TACE in Locoregional Hepatocellular Carcinoma
NCT05301842Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Mar 2022
- Primary completion
- Feb 2026
- Modality
- Antibody Conjugates, Small Molecules, Engineered Antibody Formats
- Countries
- 22
01
Overview
Phase 3, randomised, open-label trial of durvalumab, tremelimumab and lenvatinib in hepatocellular carcinoma (HCC) (3 arms), sponsored by AstraZeneca. Primary endpoint: Progression-Free Survival at 5 years. Started Mar 2022; status: active, not recruiting.
02
Drugs
durvalumabtremelimumablenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05301842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05301842.